z-logo
open-access-imgOpen Access
Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study
Author(s) -
Allen Ann,
Schenkenberger Isabelle,
Trivedi Roopa,
Cole Jeremy,
Hicks Wesley,
Gul Nadeem,
Jacques Loretta
Publication year - 2013
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.12026
Subject(s) - medicine , placebo , asthma , fluticasone propionate , corticosteroid , endocrinology , prednisolone , hypothalamic–pituitary–adrenal axis , confidence interval , fluticasone , gastroenterology , hormone , alternative medicine , pathology
Fluticasone furoate ( FF ) is a novel inhaled corticosteroid with 24‐h activity. FF is in development as a once‐daily treatment for asthma as monotherapy and in combination with vilanterol ( VI ), a long‐acting β 2 agonist. Corticosteroids can have systemic effects on hypothalamic‐pituitary‐adrenal ( HPA ) axis function, potentially resulting in cortisol suppression. Objectives To assess the effect of FF / VI compared with placebo on the HPA axis by evaluating 24‐h weighted mean serum cortisol levels in adolescent and adult patients with persistent asthma. Methods One hundred eighty‐five patients with >12 weeks history of asthma were randomised in a 4:4:4:1 ratio to one of two once‐daily FF / VI treatments (100/25 μg or 200/25 μg), placebo or an active control group that received inhaled placebo plus one prednisolone 10 mg capsule daily for the last 7 days of the study. Twenty‐four‐hour serum and urinary cortisol was measured at baseline and on day 42. Results Non‐inferiority in 24‐h weighted mean serum cortisol after 6 weeks of treatment with once‐daily FF / VI at either strength was shown. Treatment ratios [95% confidence interval ( CI )] to placebo for FF / VI 100/25 μg [0.99 (0.87–1.12)] or FF / VI 200/25 μg [0.97 (0.86–1.10)] indicated non‐inferiority of both FF / VI doses to placebo as the lower limit of the 95% CI was greater than the predefined 0.8. Prednisolone substantially reduced 24‐h weighted mean serum cortisol [treatment ratio to placebo 0.34 (0.28–0.41)]. FF / VI was well‐tolerated, and no safety concerns were identified. Conclusions FF / VI was found to be non‐inferior to placebo on HPA axis function, with no indication of significant cortisol suppression after 42 days.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here